The challenge of polypharmacy in cardiovascular medicine.
about
The polypill approach - An innovative strategy to improve cardiovascular health in Europe.Cardiovascular co-medication among users of antiobesity drugs: a population-based study.Number of medications is associated with outcomes in the elderly patient with metabolic syndrome.Use of a homecare electronic health record to find associations between patient characteristics and re-hospitalizations in patients with heart failure using telehealth.Stroke survivors', caregivers' and GPs' attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study.Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real-world' retrospective cohort study.Mechanisms of drug toxicity or intolerance.Understanding complexity in neurodegenerative diseases: in silico reconstruction of emergence.The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review.Polypharmacy in heart failure patients.Association Between Poorer Cognitive Function and Reduced Objectively Monitored Medication Adherence in Patients With Heart Failure.Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study.Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.Assessing patterns of use of cardio-protective polypill component medicines in Australian women.Connected health care: the future of health care and the role of the pharmacist.Medication Reconciliation at Discharge from Hospital: A Systematic Review of the Quantitative LiteraturePatients' experience and perceptions of polypharmacy in chronic kidney disease and its impact on adherent behaviour.
P2860
Q30398270-C2D07AEF-6318-4EEA-9682-13E5F60D0386Q34361694-59DEDC10-84F8-4D07-B517-C27916A4EBCBQ36313635-DA5B3E45-1869-4919-B18A-1300B82029F2Q36737631-9834E42C-411B-411D-AF9C-53DADF3568FFQ36920006-C4A11471-14B9-42D6-913D-706CFAFF6335Q37454789-DC6B8082-C4E7-4862-AD95-A8DC5CF52F49Q37898408-AB7E40C8-31BF-4E59-AB48-8DF7CBBF5E8EQ38039079-E41C827F-F091-4AD4-95B3-09454B53E034Q38085227-C5450BC1-CFB0-4232-8CA1-0BC927A4D860Q38184967-935D058D-7164-4973-9DCD-0D67EF2E377FQ38384130-3750CEE0-8CF9-40F1-809B-4DCDB5C59B91Q38716355-C30D521E-0D2A-479F-91F6-2E53BCCBECA9Q39440767-1CE02294-4026-490C-A0D3-C802D6C22F79Q39478333-37E9FC92-CC4D-4DC7-8EEA-57713D248C23Q39848803-AD435C2E-C9B2-41DE-B20D-2A5015F6C222Q41858595-A34F71C5-8DF7-4E1E-8682-568A32B74788Q43937613-0667E6FC-2E70-417E-A682-743D35F4C239
P2860
The challenge of polypharmacy in cardiovascular medicine.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The challenge of polypharmacy in cardiovascular medicine.
@ast
The challenge of polypharmacy in cardiovascular medicine.
@en
type
label
The challenge of polypharmacy in cardiovascular medicine.
@ast
The challenge of polypharmacy in cardiovascular medicine.
@en
prefLabel
The challenge of polypharmacy in cardiovascular medicine.
@ast
The challenge of polypharmacy in cardiovascular medicine.
@en
P2860
P1476
The challenge of polypharmacy in cardiovascular medicine.
@en
P2093
Diana Chin
Francesco Paneni
P2860
P356
10.1111/J.1472-8206.2009.00757.X
P577
2009-10-09T00:00:00Z